Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial
- 1 June 2020
- journal article
- research article
- Published by Elsevier BV in The Lancet
- Vol. 395 (10240), 1835-1844
- https://doi.org/10.1016/s0140-6736(20)30934-x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaThe New England Journal of Medicine, 2015
- Pembrolizumab versus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2015
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationThe New England Journal of Medicine, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibThe New England Journal of Medicine, 2015
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated MelanomaThe New England Journal of Medicine, 2014
- BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic MelanomaClinical Cancer Research, 2013
- Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic MelanomaClinical Cancer Research, 2012
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaThe New England Journal of Medicine, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009